Campath (Alemtuzumab) for Leukemia | MyLeukemiaTeam

Connect with others who understand.

sign up Log in
About MyLeukemiaTeam
Powered By

Campath is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat B-cell chronic lymphocytic leukemia (B-CLL). Campath may also be prescribed off-label to treat B-cell prolymphocytic leukemia (B-PLL). Campath is referred to by its drug name, alemtuzumab.

Campath is a biologic drug, a genetically engineered protein, or antibody, that targets the CD52 protein on B cells. Campath is believed to work by targeting B cells for destruction.

How do I take it?
Campath is administered as an intravenous infusion.

Campath comes in the form of a single-dose vial.

Side effects
The FDA-approved label for Campath lists common side effects including infusion reactions, low blood cell counts, nausea, vomiting, abdominal pain, insomnia, anxiety, and infections.

Rare but serious side effects listed for Campath can include severe, potentially fatal infections, infusion reactions, and low blood cell counts.

For more details about this treatment, visit:

Campath — RxList

CLL: Chemotherapy and Drug Therapy — Leukemia & Lymphoma Society

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in